FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131610691> ?p ?o ?g. }

• W2131610691 endingPage "2722" @default.
• W2131610691 startingPage "2713" @default.
• W2131610691 abstract "To evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against contemporary Gram-negative bacteria. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 10 532 Gram-negative organisms (2191 Pseudomonas aeruginosa and 8341 Enterobacteriaceae) were consecutively collected from 31 medical centres located in 13 European countries plus Turkey and Israel. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A9 document and the results interpreted according to EUCAST as well as CLSI breakpoint criteria. Selected ceftazidime- and/or meropenem-resistant P. aeruginosa isolates were screened for the presence of β-lactamase genes by PCR. P. aeruginosa exhibited high rates of multidrug-resistant (31.9%) and extensively drug-resistant (24.6%) isolates and 11.6% of isolates were susceptible only to colistin. When tested against P. aeruginosa, ceftolozane/tazobactam (MIC50, 1 mg/L) was generally 4-fold more active than ceftazidime (MIC50, 4 mg/L) and inhibited >90% of isolates with an MIC of ≤8 mg/L in nine countries. In contrast, the highest susceptibility rates observed for ceftazidime and meropenem, respectively, were 86.0%/86.0% (UK) and 85.2%/86.1% (Ireland) (67.2%/67.1% overall). Ceftolozane/tazobactam (MIC50/90, 0.25/2 mg/L; 93.7% and 95.2% inhibited at ≤4 and ≤8 mg/L, respectively), meropenem [MIC50/90, ≤0.06/≤0.06 mg/L; 98.0% susceptible (EUCAST)] and tigecycline [MIC50/90, 0.12/1 mg/L; 94.1% susceptible (EUCAST)] were the most active compounds tested against Enterobacteriaceae. Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/tazobactam when tested against Enterobacteriaceae." @default.
• W2131610691 created "2016-06-24" @default.
• W2131610691 creator A5006715126 @default.
• W2131610691 creator A5008542312 @default.
• W2131610691 creator A5026620873 @default.
• W2131610691 creator A5028739024 @default.
• W2131610691 creator A5037843249 @default.
• W2131610691 date "2014-06-10" @default.
• W2131610691 modified "2023-10-02" @default.
• W2131610691 title "Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)" @default.
• W2131610691 cites W1536681123 @default.
• W2131610691 cites W1869453106 @default.
• W2131610691 cites W1971489011 @default.
• W2131610691 cites W1984693521 @default.
• W2131610691 cites W2017698400 @default.
• W2131610691 cites W2096724428 @default.
• W2131610691 cites W2097195614 @default.
• W2131610691 cites W2117508830 @default.
• W2131610691 cites W2119644572 @default.
• W2131610691 cites W2127827046 @default.
• W2131610691 cites W2129842338 @default.
• W2131610691 cites W2133935069 @default.
• W2131610691 cites W2138299373 @default.
• W2131610691 cites W2142343447 @default.
• W2131610691 cites W2146291304 @default.
• W2131610691 cites W2152944378 @default.
• W2131610691 cites W2158444827 @default.
• W2131610691 cites W2160163108 @default.
• W2131610691 cites W2162282209 @default.
• W2131610691 doi "https://doi.org/10.1093/jac/dku184" @default.
• W2131610691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24917579" @default.
• W2131610691 hasPublicationYear "2014" @default.
• W2131610691 type Work @default.
• W2131610691 sameAs 2131610691 @default.
• W2131610691 citedByCount "131" @default.
• W2131610691 countsByYear W21316106912014 @default.
• W2131610691 countsByYear W21316106912015 @default.
• W2131610691 countsByYear W21316106912016 @default.
• W2131610691 countsByYear W21316106912017 @default.
• W2131610691 countsByYear W21316106912018 @default.
• W2131610691 countsByYear W21316106912019 @default.
• W2131610691 countsByYear W21316106912020 @default.
• W2131610691 countsByYear W21316106912021 @default.
• W2131610691 countsByYear W21316106912022 @default.
• W2131610691 countsByYear W21316106912023 @default.
• W2131610691 crossrefType "journal-article" @default.
• W2131610691 hasAuthorship W2131610691A5006715126 @default.
• W2131610691 hasAuthorship W2131610691A5008542312 @default.
• W2131610691 hasAuthorship W2131610691A5026620873 @default.
• W2131610691 hasAuthorship W2131610691A5028739024 @default.
• W2131610691 hasAuthorship W2131610691A5037843249 @default.
• W2131610691 hasBestOaLocation W21316106911 @default.
• W2131610691 hasConcept C176947019 @default.
• W2131610691 hasConcept C2775933652 @default.
• W2131610691 hasConcept C2776968632 @default.
• W2131610691 hasConcept C2777027569 @default.
• W2131610691 hasConcept C2777637488 @default.
• W2131610691 hasConcept C2778266534 @default.
• W2131610691 hasConcept C2779259085 @default.
• W2131610691 hasConcept C2779375183 @default.
• W2131610691 hasConcept C2779631663 @default.
• W2131610691 hasConcept C2780950330 @default.
• W2131610691 hasConcept C4937899 @default.
• W2131610691 hasConcept C501593827 @default.
• W2131610691 hasConcept C523546767 @default.
• W2131610691 hasConcept C54355233 @default.
• W2131610691 hasConcept C64778159 @default.
• W2131610691 hasConcept C71924100 @default.
• W2131610691 hasConcept C86803240 @default.
• W2131610691 hasConcept C89423630 @default.
• W2131610691 hasConcept C94665300 @default.
• W2131610691 hasConceptScore W2131610691C176947019 @default.
• W2131610691 hasConceptScore W2131610691C2775933652 @default.
• W2131610691 hasConceptScore W2131610691C2776968632 @default.
• W2131610691 hasConceptScore W2131610691C2777027569 @default.
• W2131610691 hasConceptScore W2131610691C2777637488 @default.
• W2131610691 hasConceptScore W2131610691C2778266534 @default.
• W2131610691 hasConceptScore W2131610691C2779259085 @default.
• W2131610691 hasConceptScore W2131610691C2779375183 @default.
• W2131610691 hasConceptScore W2131610691C2779631663 @default.
• W2131610691 hasConceptScore W2131610691C2780950330 @default.
• W2131610691 hasConceptScore W2131610691C4937899 @default.
• W2131610691 hasConceptScore W2131610691C501593827 @default.
• W2131610691 hasConceptScore W2131610691C523546767 @default.
• W2131610691 hasConceptScore W2131610691C54355233 @default.
• W2131610691 hasConceptScore W2131610691C64778159 @default.
• W2131610691 hasConceptScore W2131610691C71924100 @default.
• W2131610691 hasConceptScore W2131610691C86803240 @default.
• W2131610691 hasConceptScore W2131610691C89423630 @default.
• W2131610691 hasConceptScore W2131610691C94665300 @default.
• W2131610691 hasIssue "10" @default.
• W2131610691 hasLocation W21316106911 @default.
• W2131610691 hasLocation W21316106912 @default.
• W2131610691 hasOpenAccess W2131610691 @default.
• W2131610691 hasPrimaryLocation W21316106911 @default.
• W2131610691 hasRelatedWork W1524642279 @default.
• W2131610691 hasRelatedWork W2131610691 @default.
• W2131610691 hasRelatedWork W2944613386 @default.

• next